Company news
Mesoblast Limited (ASX:MSB) news
Every Mesoblast Limited press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Mesoblast Reports Substantial Revenue Growth to US$120M
August 26, 2026
Major Milestone Treatment Completed in P3 Trial for CLBP
August 16, 2026
Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
July 29, 2026
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
July 13, 2026
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
July 9, 2026
Mesoblast Draws US$50M from Five-Year Non-Dilutive Facility
June 24, 2026
Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
April 29, 2026
Patient Recruitment Target Achieved in CLBP Pivotal Trial
April 29, 2026
Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
April 28, 2026
Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products
April 14, 2026
Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystr...
April 10, 2026
Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation
April 8, 2026
Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystr...
April 7, 2026
Ryoncil Net Revenue for the Quarter Increases to US$30.3M
April 7, 2026
Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter
April 6, 2026
Mesoblast to Host R&D Day on April 8, 2026
March 17, 2026
Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
March 11, 2026
Ryoncil Profits Underpinning Substantial Growth Pipeline
February 26, 2026
Corporate Presentation and Half Year Financial Results
February 26, 2026
Half Year Report and Accounts (including Appendix 4D)
February 26, 2026
Ryoncil® Profits Underpinning Substantial Growth Pipeline
February 26, 2026
High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
February 11, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 28, 2026
Ryoncil® Net Revenues Increase for the Quarter to US$30M
January 28, 2026
Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
January 26, 2026
FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy
January 18, 2026
Ryoncil Sales for the Quarter Increase 60% to US$35.1M
January 8, 2026
Ryoncil® Sales Increase 60% in December Quarter to US$35.1M
January 8, 2026
Mesoblast Announces Changes to Board of Directors' Leadership Roles
January 1, 2026
Mesoblast Enters into Non-Dilutive Lower Cost 5-Year Credit
December 29, 2025
Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line
December 29, 2025
Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Cli...
December 11, 2025
Mesoblast Participation at Piper Sandler Conference
December 3, 2025
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors
December 1, 2025
Ryoncil Revenue Growth Highlighted in AGM Trading Update
November 24, 2025
CEO Presentation to 2025 Annual General Meeting
November 24, 2025
Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue
November 24, 2025
Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to ...
November 20, 2025
James M. O’Brien Appointed Chief Financial Officer at Mesoblast
November 17, 2025
Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation
November 4, 2025
Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch
October 19, 2025
Ryoncil Revenues Increase 66% in Second Quarter Post Launch
October 6, 2025
Ryoncil® Revenues Increase 66% in Second Quarter Post Launch
October 6, 2025
Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access
October 2, 2025
Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs
September 26, 2025
Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences
September 14, 2025
Mesoblast Option to Issue up to US$50m Convertible Notes
September 4, 2025
Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes
September 3, 2025
MSB Annual Financial Results and Operational Update
August 28, 2025
Annual Financial Results Presentation
August 28, 2025